Form 4 for ATOS ATOSSA THERAPEUTICS, INC.
Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-20 · accession 0001437749-23-017896 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-20 | 2023-06-20 | ATOS | WEAVER GREGORY L | EVP, CFO, Dir | P - Purchase | $0.97 | +50.0K | 50.1K | +90,909% | +$48.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-20 | P | A | 50,000 | $0.97 | 50,055 | D | — | — | (F1) The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.99. Upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. (F2) Includes shares of common stock purchased on November 21, 2013, which were previously reported on a Form 4 filed by the Reporting Person on November 22, 2013 but erroneously omitted in subsequent filings. |